NDAORALTABLET
Approved
Oct 1957
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
4/8 — Partial
MEDROL (methylprednisolone) by Pfizer is corticosteroid hormone receptor agonists [moa]. First approved in 1957.
Drug data last refreshed 4d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
MEDROL (methylprednisolone) is an oral corticosteroid that works by agonizing glucocorticoid receptors to suppress immune and inflammatory responses. It treats a broad portfolio spanning transplant rejection, autoimmune diseases (rheumatoid arthritis, lupus, MS), hematologic malignancies, and acute respiratory conditions. The drug's wide indication range reflects its potent anti-inflammatory and immunosuppressive properties across multiple therapeutic areas.
$11KPart D
LOE ApproachingProduct approaching loss of exclusivity with minimal Part D spend signals mature market phase; brand teams should focus on lifecycle management and defending market position against generics rather than growth initiatives.
Mechanism of Action
Corticosteroid Hormone Receptor Agonists
Pharmacologic Class:
Corticosteroid
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
Efficacy and Safety of Methylprednisolone After Flow-Diverter Stent Implantation in Unruptured Intracranial Aneurysms
Started Jan 2026
864 enrolled
Unruptured Intracranial AneurysmsCerebrovascular EventHemorrhagic Stroke+2 more
Evaluating Premedication Regimens (Methylprednisolone vs Dexamethasone-based) for the Prevention of Systemic and Injection Site Reactions to Motixafortide in Patients With Multiple Myeloma Undergoing Stem Cell Mobilization, PARADE Trial
Started Sep 2025
94 enrolled
Multiple Myeloma
The Effect of Methylprednisolone on the Reversal Time of Rocuronium by Sugammadex in the Pediatric Patient Group
Started Oct 2024
Depo-Medrol on Psoas After LLIF
Started May 2023
80 enrolled
Muscle WeaknessPain, PostoperativeParesthesia+1 more
Rapamycin Plus Methylprednisolone Versus Methylprednisolone Alone in Active, Moderate-to-severe Graves' Orbitopathy.
Started Sep 2022
140 enrolled
Graves Ophthalmopathy
Worked on MEDROL at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.